Clinical Diagnosis, Viral PCR, and Antibiotic Utilization in Community-Acquired Pneumonia

被引:9
作者
Afzal, Zeeshan [1 ]
Minard, Charles G. [2 ]
Stager, Charles E. [3 ]
Yu, Victor L. [4 ]
Musher, Daniel M. [1 ,5 ]
机构
[1] Baylor Coll Med, Sect Infect Dis, Dept Med, Houston, TX 77030 USA
[2] Baylor Coll Med, Dan L Duncan Inst Clin & Translat Res, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[4] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA
[5] Michael E DeBakey VA Med Ctr, Med Care Line, Infect Dis Sect, 2002 Holcombe Blvd,4B-370C, Houston, TX 77030 USA
关键词
CAP; viral PCR; antibiotic stewardship; INFECTIOUS-DISEASES-SOCIETY; ANTIMICROBIAL STEWARDSHIP; MANAGEMENT; ADULTS; THERAPY; GUIDELINES; DURATION; OUTCOMES; IMPACT; RESISTANCE;
D O I
10.1097/MJT.0000000000000018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We evaluated the intensity of antibiotic therapy in patients in whom the etiology of community-acquired pneumonia (CAP) was determined using newly available diagnostic techniques. For 1 year, we studied all patients admitted for findings consistent with CAP. Sputum and blood cultures, urinary pneumococcal and Legionella antigens, and viral polymerase chain reaction (PCR) were studied prospectively. Patients were stratified based on the final diagnoses: proven bacterial, presumptive bacterial, viral, fungal, undetermined, and uninfected. We determined the number of antibiotics given, duration of antibiotic therapy, and intensity of antibiotic use determined by antibiotic-days defined as the sum, in each patient, of all antibiotics given for CAP and the number of days given. Median duration and intensity of antibiotics were 12 and 18 days for proven, and 13 and 16.5 days for presumed bacterial CAP (P > 0.9). When positive viral PCR results were not disclosed to primary care physicians, antibiotic use was similar to that in bacterial CAP. However, in 11 cases, when positive viral PCR results were disclosed, duration and intensity of antibiotic use were reduced to 7 and 9 days, respectively (P = 0.05 and 0.08, respectively). Antibiotic use was similar in patients with bacterial pneumonia and those judged on clinical grounds to have likely nonbacterial infection. Despite obvious differences in clinical syndromes and final diagnoses, the intensity of antibiotic therapy was similar in all groups of patients admitted for CAP with the exception of those who were uninfected and whose primary care physicians were informed of a positive viral PCR.
引用
收藏
页码:e766 / e772
页数:7
相关论文
共 50 条
  • [41] Effects of a clinical pathway on antibiotic use in patients with community-acquired pneumonia: a multi-site study in China
    Zhu, Liping
    Bai, Jie
    Chen, Yongcong
    Xue, Di
    BMC INFECTIOUS DISEASES, 2018, 18
  • [42] Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population
    Murcia, J. M.
    Gonzalez-Comeche, J.
    Marin, A.
    Barberan, J.
    Granizo, J. J.
    Aguilar, L.
    Gonzalez-Moreno, J.
    Gonzalez-Pina, B.
    Lopez-Dupla, M.
    Irurzun, J.
    CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 (11) : 1046 - 1050
  • [43] Community-acquired Pneumonia and Hospital-acquired Pneumonia
    Lanks, Charles W.
    Musani, Ali, I
    Hsia, David W.
    MEDICAL CLINICS OF NORTH AMERICA, 2019, 103 (03) : 487 - +
  • [44] Time to Clinical Stability in Children With Community-Acquired Pneumonia
    Field, Madeline R.
    Ambroggio, Lilliam
    Lorenz, Douglas
    Shah, Samir S.
    Ruddy, Richard M.
    Florin, Todd A.
    PEDIATRICS, 2024, 153 (05)
  • [45] The effect of the antibiotic stewardship program (ASP) on community-acquired pneumonia (CAP): a before-after study
    Fesus, Adina
    Baluku, Phiona
    Sipos, Eva
    Somodi, Sandor
    Berczi-Kun, Eniko
    Lekli, Istvan
    Bacskay, Ildiko
    Benko, Ria
    Vasko, Attila
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [46] Improved clinical outcomes with utilization of a community-acquired pneumonia guideline
    Dean, Nathan C.
    Bateman, Kim A.
    Donnelly, Steven M.
    Silver, Michael P.
    Snow, Greg L.
    Hale, David
    CHEST, 2006, 130 (03) : 794 - 799
  • [47] Effects of clinical pathway implementation on antibiotic prescriptions for pediatric community-acquired pneumonia
    Dona, Daniele
    Zingarella, Silvia
    Gastaldi, Andrea
    Lundin, Rebecca
    Perilongo, Giorgio
    Frigo, Anna Chiara
    Hamdy, Rana F.
    Zaoutis, Theoklis
    Da Dalt, Liviana
    Giaquinto, Carlo
    PLOS ONE, 2018, 13 (02):
  • [48] Duration of Antibiotic Treatment in Community-Acquired Pneumonia A Multicenter Randomized Clinical Trial
    Uranga, Ane
    Espana, Pedro P.
    Bilbao, Amaia
    Quintana, Jose Maria
    Arriaga, Ignacio
    Intxausti, Maider
    Lobo, Jose Luis
    Tomas, Laura
    Camino, Jesus
    Nunez, Juan
    Capelastegui, Alberto
    JAMA INTERNAL MEDICINE, 2016, 176 (09) : 1257 - 1265
  • [49] Individualizing duration of antibiotic therapy in community-acquired pneumonia
    Aliberti, Stefano
    Ramirez, Julio
    Giuliani, Fabio
    Wiemken, Timothy
    Sotgiu, Giovanni
    Tedeschi, Sara
    Carugati, Manuela
    Valenti, Vincenzo
    Marchioni, Marco
    Camera, Marco
    Piro, Roberto
    Del Forno, Manuela
    Milani, Giuseppe
    Faverio, Paola
    Richeldi, Luca
    Deotto, Martina
    Villani, Massimiliano
    Voza, Antonio
    Tobaldini, Eleonora
    Bernardi, Mauro
    Bellone, Andrea
    Bassetti, Matteo
    Blasi, Francesco
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 : 191 - 201
  • [50] Diagnostic stewardship aiming at expectorated or induced sputum promotes microbial diagnosis in community-acquired pneumonia
    Waagsbo, Bjorn
    Buset, Eva Margrethe
    Longva, Jorn-Age
    Bjerke, Merete
    Bakkene, Birgitte
    Ertesvag, Anne-Stine
    Holmen, Hanne
    Nikodojevic, Marko
    Tran, To Thy
    Christensen, Andreas
    Nilsen, Einar
    Damas, Jan Kristian
    Heggelund, Lars
    BMC INFECTIOUS DISEASES, 2022, 22 (01)